Extracorporeal Photopheresis After Lung Transplantation : A 10-Year Single-Center Experience
We report the largest single-center experience with extracorporeal photopheresis (ECP) for bronchiolitis obliterans syndrome (BOS) and recurrent acute rejection (AR) after lung transplantation. Lung transplant recipients undergoing ECP for BOS and recurrent AR were included (1997-2007). The rate of...
Gespeichert in:
| Veröffentlicht in: | Transplantation 2008-12, Vol.86 (11), p.1625-1627 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1627 |
|---|---|
| container_issue | 11 |
| container_start_page | 1625 |
| container_title | Transplantation |
| container_volume | 86 |
| creator | BENDEN, Christian SPEICH, Rudolf HOFBAUER, Günther F IRANI, Sarosh EICH-WANGER, Christine RUSSI, Erich W WEDER, Walter BOEHLER, Annette |
| description | We report the largest single-center experience with extracorporeal photopheresis (ECP) for bronchiolitis obliterans syndrome (BOS) and recurrent acute rejection (AR) after lung transplantation. Lung transplant recipients undergoing ECP for BOS and recurrent AR were included (1997-2007). The rate of forced expiratory volume in 1 second (FEV1) decline was used as the primary measure and graft survival post-ECP as the secondary measure of efficacy. Twenty-four transplant recipients were included (BOS, n=12; recurrent AR, n=12). In recipients with BOS, decline in FEV1 was 112 mL/month before the start of ECP and 12 mL/month after 12 ECP cycles (P=0.011), mean (95% CI) change in rate of decline was 100 (28-171). Median patient survival was 7.0 (range, 3.0-13.6) years, median patient survival post-ECP 4.9 (range, 0.5-8.4) years. No ECP-related complications occurred. Extracorporeal photopheresis reduces the rate of lung function decline in recipients with BOS and is well tolerated. Furthermore, recipients with recurrent AR experience clinical stabilization. However, the underlying mechanism of ECP remains subject to further research. |
| doi_str_mv | 10.1097/TP.0b013e31818bc024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69908591</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69908591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-9ed85cf51c46bc460b01c4016197cdad27091dc7cfef00c58b34b8001e512d373</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRbK3-AkFy0VvqTDbJ7norpX5AwYL1IAhhs5m0kTSJuynUf29Ci4IXD8Mc5pmXmYexS4QxghK3y8UYUkBOHCXK1EAQHrEhRjz0Y5BwzIYAIfrIuRiwM-c-ACDiQpyyASoQQgEM2fts11ptatvUlnTpLdZ1WzdrsuQK503ylqw331Yrb2l15ZpSV61ui7ry7ryJh-C_kbbeS1GtSvKnVPX4bNeQLagydM5Ocl06ujj0EXu9ny2nj_78-eFpOpn7JgTV-ooyGZk8QhPGaVf9V90EY1TCZDoLBCjMjDA55QAmkikPUwmAFGGQccFH7Gaf29j6c0uuTTaFM1R211K9dUmsFMhI4b9gAF1awHuQ70Fja-cs5Ulji422XwlC0ttPlovkr_1u6-oQv003lP3uHHR3wPUB0M7oMu-cmsL9cAGoKJAy5t-3TI11</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20373231</pqid></control><display><type>article</type><title>Extracorporeal Photopheresis After Lung Transplantation : A 10-Year Single-Center Experience</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>BENDEN, Christian ; SPEICH, Rudolf ; HOFBAUER, Günther F ; IRANI, Sarosh ; EICH-WANGER, Christine ; RUSSI, Erich W ; WEDER, Walter ; BOEHLER, Annette</creator><creatorcontrib>BENDEN, Christian ; SPEICH, Rudolf ; HOFBAUER, Günther F ; IRANI, Sarosh ; EICH-WANGER, Christine ; RUSSI, Erich W ; WEDER, Walter ; BOEHLER, Annette</creatorcontrib><description>We report the largest single-center experience with extracorporeal photopheresis (ECP) for bronchiolitis obliterans syndrome (BOS) and recurrent acute rejection (AR) after lung transplantation. Lung transplant recipients undergoing ECP for BOS and recurrent AR were included (1997-2007). The rate of forced expiratory volume in 1 second (FEV1) decline was used as the primary measure and graft survival post-ECP as the secondary measure of efficacy. Twenty-four transplant recipients were included (BOS, n=12; recurrent AR, n=12). In recipients with BOS, decline in FEV1 was 112 mL/month before the start of ECP and 12 mL/month after 12 ECP cycles (P=0.011), mean (95% CI) change in rate of decline was 100 (28-171). Median patient survival was 7.0 (range, 3.0-13.6) years, median patient survival post-ECP 4.9 (range, 0.5-8.4) years. No ECP-related complications occurred. Extracorporeal photopheresis reduces the rate of lung function decline in recipients with BOS and is well tolerated. Furthermore, recipients with recurrent AR experience clinical stabilization. However, the underlying mechanism of ECP remains subject to further research.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/TP.0b013e31818bc024</identifier><identifier>PMID: 19077900</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Biological and medical sciences ; Bronchiolitis Obliterans - therapy ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Graft Survival ; Humans ; Immunosuppressive Agents - therapeutic use ; Lung - physiopathology ; Lung Transplantation - methods ; Male ; Medical sciences ; Middle Aged ; Photopheresis - adverse effects ; Recurrence ; Retrospective Studies ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tissue, organ and graft immunology ; Treatment Outcome</subject><ispartof>Transplantation, 2008-12, Vol.86 (11), p.1625-1627</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-9ed85cf51c46bc460b01c4016197cdad27091dc7cfef00c58b34b8001e512d373</citedby><cites>FETCH-LOGICAL-c409t-9ed85cf51c46bc460b01c4016197cdad27091dc7cfef00c58b34b8001e512d373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20952886$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19077900$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BENDEN, Christian</creatorcontrib><creatorcontrib>SPEICH, Rudolf</creatorcontrib><creatorcontrib>HOFBAUER, Günther F</creatorcontrib><creatorcontrib>IRANI, Sarosh</creatorcontrib><creatorcontrib>EICH-WANGER, Christine</creatorcontrib><creatorcontrib>RUSSI, Erich W</creatorcontrib><creatorcontrib>WEDER, Walter</creatorcontrib><creatorcontrib>BOEHLER, Annette</creatorcontrib><title>Extracorporeal Photopheresis After Lung Transplantation : A 10-Year Single-Center Experience</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>We report the largest single-center experience with extracorporeal photopheresis (ECP) for bronchiolitis obliterans syndrome (BOS) and recurrent acute rejection (AR) after lung transplantation. Lung transplant recipients undergoing ECP for BOS and recurrent AR were included (1997-2007). The rate of forced expiratory volume in 1 second (FEV1) decline was used as the primary measure and graft survival post-ECP as the secondary measure of efficacy. Twenty-four transplant recipients were included (BOS, n=12; recurrent AR, n=12). In recipients with BOS, decline in FEV1 was 112 mL/month before the start of ECP and 12 mL/month after 12 ECP cycles (P=0.011), mean (95% CI) change in rate of decline was 100 (28-171). Median patient survival was 7.0 (range, 3.0-13.6) years, median patient survival post-ECP 4.9 (range, 0.5-8.4) years. No ECP-related complications occurred. Extracorporeal photopheresis reduces the rate of lung function decline in recipients with BOS and is well tolerated. Furthermore, recipients with recurrent AR experience clinical stabilization. However, the underlying mechanism of ECP remains subject to further research.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Bronchiolitis Obliterans - therapy</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Lung - physiopathology</subject><subject>Lung Transplantation - methods</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Photopheresis - adverse effects</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Tissue, organ and graft immunology</subject><subject>Treatment Outcome</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1Lw0AQhhdRbK3-AkFy0VvqTDbJ7norpX5AwYL1IAhhs5m0kTSJuynUf29Ci4IXD8Mc5pmXmYexS4QxghK3y8UYUkBOHCXK1EAQHrEhRjz0Y5BwzIYAIfrIuRiwM-c-ACDiQpyyASoQQgEM2fts11ptatvUlnTpLdZ1WzdrsuQK503ylqw331Yrb2l15ZpSV61ui7ry7ryJh-C_kbbeS1GtSvKnVPX4bNeQLagydM5Ocl06ujj0EXu9ny2nj_78-eFpOpn7JgTV-ooyGZk8QhPGaVf9V90EY1TCZDoLBCjMjDA55QAmkikPUwmAFGGQccFH7Gaf29j6c0uuTTaFM1R211K9dUmsFMhI4b9gAF1awHuQ70Fja-cs5Ulji422XwlC0ttPlovkr_1u6-oQv003lP3uHHR3wPUB0M7oMu-cmsL9cAGoKJAy5t-3TI11</recordid><startdate>20081215</startdate><enddate>20081215</enddate><creator>BENDEN, Christian</creator><creator>SPEICH, Rudolf</creator><creator>HOFBAUER, Günther F</creator><creator>IRANI, Sarosh</creator><creator>EICH-WANGER, Christine</creator><creator>RUSSI, Erich W</creator><creator>WEDER, Walter</creator><creator>BOEHLER, Annette</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20081215</creationdate><title>Extracorporeal Photopheresis After Lung Transplantation : A 10-Year Single-Center Experience</title><author>BENDEN, Christian ; SPEICH, Rudolf ; HOFBAUER, Günther F ; IRANI, Sarosh ; EICH-WANGER, Christine ; RUSSI, Erich W ; WEDER, Walter ; BOEHLER, Annette</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-9ed85cf51c46bc460b01c4016197cdad27091dc7cfef00c58b34b8001e512d373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Bronchiolitis Obliterans - therapy</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Lung - physiopathology</topic><topic>Lung Transplantation - methods</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Photopheresis - adverse effects</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Tissue, organ and graft immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BENDEN, Christian</creatorcontrib><creatorcontrib>SPEICH, Rudolf</creatorcontrib><creatorcontrib>HOFBAUER, Günther F</creatorcontrib><creatorcontrib>IRANI, Sarosh</creatorcontrib><creatorcontrib>EICH-WANGER, Christine</creatorcontrib><creatorcontrib>RUSSI, Erich W</creatorcontrib><creatorcontrib>WEDER, Walter</creatorcontrib><creatorcontrib>BOEHLER, Annette</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BENDEN, Christian</au><au>SPEICH, Rudolf</au><au>HOFBAUER, Günther F</au><au>IRANI, Sarosh</au><au>EICH-WANGER, Christine</au><au>RUSSI, Erich W</au><au>WEDER, Walter</au><au>BOEHLER, Annette</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extracorporeal Photopheresis After Lung Transplantation : A 10-Year Single-Center Experience</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>2008-12-15</date><risdate>2008</risdate><volume>86</volume><issue>11</issue><spage>1625</spage><epage>1627</epage><pages>1625-1627</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>We report the largest single-center experience with extracorporeal photopheresis (ECP) for bronchiolitis obliterans syndrome (BOS) and recurrent acute rejection (AR) after lung transplantation. Lung transplant recipients undergoing ECP for BOS and recurrent AR were included (1997-2007). The rate of forced expiratory volume in 1 second (FEV1) decline was used as the primary measure and graft survival post-ECP as the secondary measure of efficacy. Twenty-four transplant recipients were included (BOS, n=12; recurrent AR, n=12). In recipients with BOS, decline in FEV1 was 112 mL/month before the start of ECP and 12 mL/month after 12 ECP cycles (P=0.011), mean (95% CI) change in rate of decline was 100 (28-171). Median patient survival was 7.0 (range, 3.0-13.6) years, median patient survival post-ECP 4.9 (range, 0.5-8.4) years. No ECP-related complications occurred. Extracorporeal photopheresis reduces the rate of lung function decline in recipients with BOS and is well tolerated. Furthermore, recipients with recurrent AR experience clinical stabilization. However, the underlying mechanism of ECP remains subject to further research.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>19077900</pmid><doi>10.1097/TP.0b013e31818bc024</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1337 |
| ispartof | Transplantation, 2008-12, Vol.86 (11), p.1625-1627 |
| issn | 0041-1337 1534-6080 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69908591 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Biological and medical sciences Bronchiolitis Obliterans - therapy Female Fundamental and applied biological sciences. Psychology Fundamental immunology Graft Survival Humans Immunosuppressive Agents - therapeutic use Lung - physiopathology Lung Transplantation - methods Male Medical sciences Middle Aged Photopheresis - adverse effects Recurrence Retrospective Studies Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Tissue, organ and graft immunology Treatment Outcome |
| title | Extracorporeal Photopheresis After Lung Transplantation : A 10-Year Single-Center Experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T02%3A54%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extracorporeal%20Photopheresis%20After%20Lung%20Transplantation%20:%20A%2010-Year%20Single-Center%20Experience&rft.jtitle=Transplantation&rft.au=BENDEN,%20Christian&rft.date=2008-12-15&rft.volume=86&rft.issue=11&rft.spage=1625&rft.epage=1627&rft.pages=1625-1627&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/TP.0b013e31818bc024&rft_dat=%3Cproquest_cross%3E69908591%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20373231&rft_id=info:pmid/19077900&rfr_iscdi=true |